| 白慧霞,武春燕,段春霞,武 云,朱 巍,白雪莲,于德东,赵丽凤.西妥昔单抗联合伊立替康对晚期胃癌患者血清肿瘤标志物、T淋巴细胞亚群水平及生活质量的影响[J].,2022,(21):4157-4162 |
| 西妥昔单抗联合伊立替康对晚期胃癌患者血清肿瘤标志物、T淋巴细胞亚群水平及生活质量的影响 |
| Effects of Cetuximab Combined with Irinotecan on Serum Tumor Markers, T Lymphocyte Subsets Levels and Quality of Life in Patients with Advanced Gastric Cancer |
| 投稿时间：2022-05-03 修订日期：2022-05-26 |
| DOI：10.13241/j.cnki.pmb.2022.21.029 |
| 中文关键词: 西妥昔单抗 伊立替康 晚期胃癌 血清肿瘤标志物 T淋巴细胞亚群 生活质量 |
| 英文关键词: Cetuximab Irinotecan Advanced gastric cancer Serum tumor markers T lymphocyte subsets Quality of life |
| 基金项目:内蒙古自治区卫生和计划生育委员会项目（201503128） |
|
| 摘要点击次数: 780 |
| 全文下载次数: 442 |
| 中文摘要: |
| 摘要 目的：探讨西妥昔单抗联合伊立替康治疗晚期胃癌对患者血清肿瘤标志物、T淋巴细胞亚群水平及生活质量的影响。方法：选取2018年4月~2020年4月于包头市中心医院接受诊治的104例晚期胃癌患者，按治疗方案不同分为对照组（52例）与观察组（52例），对照组接受西妥昔单抗治疗，观察组接受西妥昔单抗联合伊立替康治疗，对比两组临床疗效、不良反应、血清肿瘤标志物、生活质量、T淋巴细胞亚群水平及预后情况。结果：观察组的临床有效率为65.38%，高于对照组的25.00%（P＜0.05）；观察组的疾病控制率为71.15%，高于对照组的34.62%（P＜0.05）。与对照组比较，观察组治疗后糖类抗原199（CA199）、糖类抗原724（CA724）和癌胚抗原（CEA）水平更低（P＜0.05）。CD3+、CD4+、CD4+/CD8+水平比较，观察组治疗后均高于对照组（P＜0.05）；CD8+水平比较，观察组治疗后较对照组低（P＜0.05）。观察组治疗后各项生活质量评分均高于对照组（P＜0.05）。观察组不良反应发生率为13.46%，低于对照组的15.38%，但无明显差异（P＞0.05）。对照组治疗后1年中位生存期为6.16个月，短于观察组的8.34个月，差异有统计学意义（Logrank x2= 4.219，P=0.040）。结论：西妥昔单抗联合伊立替康治疗晚期胃癌，可有效阻止肿瘤进展，提高临床有效率和患者生活质量，改善T淋巴细胞亚群水平，延长患者生存期，且安全性较好。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of cetuximab combined with irinotecan on serum tumor markers, T lymphocyte subsets and quality of life in patients with advanced gastric cancer. Methods: 104 patients with advanced gastric cancer who were treated in Baotou Central Hospital from April 2018 to April 2020 were seleced, and they were divided into control group (52 cases) and observation group (52 cases) according to different treatment schemes. The control group was treated with cetuximab, and the observation group was treated with cetuximab combined with irinotecan. The clinical efficacy, adverse reactions, serum tumor markers, quality of life, T lymphocyte subsets and prognosis of the two groups were compared. Results: The clinical effective rate of the observation group was 65.38%, which was higher than 25.00% of the control group (P<0.05). The disease control rate in the observation group was 71.15%, which was higher than 34.62% in the control group (P<0.05). Compared with the control group, the levels of carbohydrate antigen 199 (CA199), carbohydrate antigen 724 (CA724) and carcinoembryonic antigen (CEA) in the observation group were lower after treatment (P<0.05). The levels of CD3+, CD4+, CD4+/CD8+ in the observation group were higher than those in the control group after treatment (P<0.05). The level of CD8+ in the observation group was lower than that in the control group after treatment (P<0.05). After treatment, the scores of quality of life in the observation group were higher than those in the control group (P<0.05). The incidence of adverse reactions in the observation group was 13.46%, lower than 15.38% in the control group, but there was no significant difference (P>0.05). The 1-year median survival time of the control group was 6.16 months, which was shorter than 8.34 months of the observation group (logrank x2=4.219，P=0.040). Conclusion: cetuximab combined with irinotecan in the treatment of advanced gastric cancer can effectively prevent tumor progression, improve clinical efficiency and quality of life, improve the level of T lymphocyte subsets, prolong the survival time of patients, and have good safety. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
